The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693

J. P. Van Der Post, S. J. De Visser, M. L. De Kam, M. Woelfler, D. C. Hilt, J. Vornov, E. S. Burak, E. Bortey, Barbara Slusher, T. Limsakun, A. F. Cohen, J. M A Van Gerven

Research output: Contribution to journalArticle

Abstract

Aim: The aim was to assess the central nervous system (CNS) effects, pharmacokinetics and safety of GPI 5693, an inhibitor of a novel CNS-drug target, NAALADase which is being evaluated for the treatment of neuropathic pain. Methods: This was a double-blind, placebo-controlled, exploratory study in healthy subjects receiving oral GPI 5693 single ascending doses of 100, 300, 750, 1125 mg with a placebo treatment randomly interspersed. An open-label, parallel extension examined the effects of food and sex on the pharmacokinetics of 750, 1125 and 1500 mg doses. Blood samples were collected for pharmacokinetic and biochemical/haematological safety analysis, vital signs, ECG and adverse event checks were performed regularly up to 48 h postdose. Postdose CNS effects were assessed using eye movements, adaptive tracking, electroencephalography (EEC), body sway and Visual Analogue Scales (VAS). Results: CNS effects were mainly observed after the 1125 mg dose, showing a significant decrease of adaptive tracking performance, VAS alertness and VAS mood, and an increase of EEG occipital alpha and theta power. Gastro-intestinal (GI) adverse effects were frequent at higher doses. No clinically significant changes in vital signs or ECG were noted during any of the treatments. The therapeutically relevant concentration range (950-11 100 ng ml-1) as determined from animal experiments was already reached after the 300 mg dose. Cmax after the 300 mg and 750 mg dose was 2868 and 9266 ng ml-1 with a t 1/2 of 2.54 and 4.78 h, respectively. Concomitant food intake (with the 750 mg and 1125 mg doses) reduced Cmax by approximately 66% and AUC by approximately 40%. With concomitant food intake, the dose-normalized Cmax also decreased significantly by -5.6 (CI: -2.6 to -8.7) ng ml-1 mg-1. The pharmacokinetic variability was largest after the 300 mg and 750 mg dose, resulting in a SD of approximately 50% of the Cmax. Conclusion: NAALADase inhibition with GPI 5693 was safe and tolerable in healthy subjects. Plasma concentrations that were effective in the reversal of hyperalgesia in the chronic constrictive injury animal model of neuropathic pain were obtained at doses of 300, 750 and 1125 mg in the fasted state. Comcomitant food intake reduced Cmax and AUC. CNS effects and GI AEs increased in incidence over placebo only at the 1125 mg dose.

Original languageEnglish (US)
Pages (from-to)128-136
Number of pages9
JournalBritish Journal of Clinical Pharmacology
Volume60
Issue number2
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Glutamate Carboxypeptidase II
Central Nervous System
Pharmacokinetics
Visual Analog Scale
Safety
Vital Signs
Eating
Placebos
Neuralgia
Area Under Curve
Electroencephalography
Healthy Volunteers
Electrocardiography
Central Nervous System Agents
Hyperalgesia
Eye Movements
Therapeutics
Animal Models
Food
2-(3-mercaptopropyl)pentanedioic acid

Keywords

  • Central nervous system
  • NAALAD-ase-inhibitor
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Van Der Post, J. P., De Visser, S. J., De Kam, M. L., Woelfler, M., Hilt, D. C., Vornov, J., ... Van Gerven, J. M. A. (2005). The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. British Journal of Clinical Pharmacology, 60(2), 128-136. https://doi.org/10.1111/j.1365-2125.2005.02396.x

The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. / Van Der Post, J. P.; De Visser, S. J.; De Kam, M. L.; Woelfler, M.; Hilt, D. C.; Vornov, J.; Burak, E. S.; Bortey, E.; Slusher, Barbara; Limsakun, T.; Cohen, A. F.; Van Gerven, J. M A.

In: British Journal of Clinical Pharmacology, Vol. 60, No. 2, 08.2005, p. 128-136.

Research output: Contribution to journalArticle

Van Der Post, JP, De Visser, SJ, De Kam, ML, Woelfler, M, Hilt, DC, Vornov, J, Burak, ES, Bortey, E, Slusher, B, Limsakun, T, Cohen, AF & Van Gerven, JMA 2005, 'The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693', British Journal of Clinical Pharmacology, vol. 60, no. 2, pp. 128-136. https://doi.org/10.1111/j.1365-2125.2005.02396.x
Van Der Post, J. P. ; De Visser, S. J. ; De Kam, M. L. ; Woelfler, M. ; Hilt, D. C. ; Vornov, J. ; Burak, E. S. ; Bortey, E. ; Slusher, Barbara ; Limsakun, T. ; Cohen, A. F. ; Van Gerven, J. M A. / The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. In: British Journal of Clinical Pharmacology. 2005 ; Vol. 60, No. 2. pp. 128-136.
@article{5455572c1d2c46cfa7a83d76a4061d15,
title = "The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693",
abstract = "Aim: The aim was to assess the central nervous system (CNS) effects, pharmacokinetics and safety of GPI 5693, an inhibitor of a novel CNS-drug target, NAALADase which is being evaluated for the treatment of neuropathic pain. Methods: This was a double-blind, placebo-controlled, exploratory study in healthy subjects receiving oral GPI 5693 single ascending doses of 100, 300, 750, 1125 mg with a placebo treatment randomly interspersed. An open-label, parallel extension examined the effects of food and sex on the pharmacokinetics of 750, 1125 and 1500 mg doses. Blood samples were collected for pharmacokinetic and biochemical/haematological safety analysis, vital signs, ECG and adverse event checks were performed regularly up to 48 h postdose. Postdose CNS effects were assessed using eye movements, adaptive tracking, electroencephalography (EEC), body sway and Visual Analogue Scales (VAS). Results: CNS effects were mainly observed after the 1125 mg dose, showing a significant decrease of adaptive tracking performance, VAS alertness and VAS mood, and an increase of EEG occipital alpha and theta power. Gastro-intestinal (GI) adverse effects were frequent at higher doses. No clinically significant changes in vital signs or ECG were noted during any of the treatments. The therapeutically relevant concentration range (950-11 100 ng ml-1) as determined from animal experiments was already reached after the 300 mg dose. Cmax after the 300 mg and 750 mg dose was 2868 and 9266 ng ml-1 with a t 1/2 of 2.54 and 4.78 h, respectively. Concomitant food intake (with the 750 mg and 1125 mg doses) reduced Cmax by approximately 66{\%} and AUC by approximately 40{\%}. With concomitant food intake, the dose-normalized Cmax also decreased significantly by -5.6 (CI: -2.6 to -8.7) ng ml-1 mg-1. The pharmacokinetic variability was largest after the 300 mg and 750 mg dose, resulting in a SD of approximately 50{\%} of the Cmax. Conclusion: NAALADase inhibition with GPI 5693 was safe and tolerable in healthy subjects. Plasma concentrations that were effective in the reversal of hyperalgesia in the chronic constrictive injury animal model of neuropathic pain were obtained at doses of 300, 750 and 1125 mg in the fasted state. Comcomitant food intake reduced Cmax and AUC. CNS effects and GI AEs increased in incidence over placebo only at the 1125 mg dose.",
keywords = "Central nervous system, NAALAD-ase-inhibitor, Pharmacokinetics",
author = "{Van Der Post}, {J. P.} and {De Visser}, {S. J.} and {De Kam}, {M. L.} and M. Woelfler and Hilt, {D. C.} and J. Vornov and Burak, {E. S.} and E. Bortey and Barbara Slusher and T. Limsakun and Cohen, {A. F.} and {Van Gerven}, {J. M A}",
year = "2005",
month = "8",
doi = "10.1111/j.1365-2125.2005.02396.x",
language = "English (US)",
volume = "60",
pages = "128--136",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693

AU - Van Der Post, J. P.

AU - De Visser, S. J.

AU - De Kam, M. L.

AU - Woelfler, M.

AU - Hilt, D. C.

AU - Vornov, J.

AU - Burak, E. S.

AU - Bortey, E.

AU - Slusher, Barbara

AU - Limsakun, T.

AU - Cohen, A. F.

AU - Van Gerven, J. M A

PY - 2005/8

Y1 - 2005/8

N2 - Aim: The aim was to assess the central nervous system (CNS) effects, pharmacokinetics and safety of GPI 5693, an inhibitor of a novel CNS-drug target, NAALADase which is being evaluated for the treatment of neuropathic pain. Methods: This was a double-blind, placebo-controlled, exploratory study in healthy subjects receiving oral GPI 5693 single ascending doses of 100, 300, 750, 1125 mg with a placebo treatment randomly interspersed. An open-label, parallel extension examined the effects of food and sex on the pharmacokinetics of 750, 1125 and 1500 mg doses. Blood samples were collected for pharmacokinetic and biochemical/haematological safety analysis, vital signs, ECG and adverse event checks were performed regularly up to 48 h postdose. Postdose CNS effects were assessed using eye movements, adaptive tracking, electroencephalography (EEC), body sway and Visual Analogue Scales (VAS). Results: CNS effects were mainly observed after the 1125 mg dose, showing a significant decrease of adaptive tracking performance, VAS alertness and VAS mood, and an increase of EEG occipital alpha and theta power. Gastro-intestinal (GI) adverse effects were frequent at higher doses. No clinically significant changes in vital signs or ECG were noted during any of the treatments. The therapeutically relevant concentration range (950-11 100 ng ml-1) as determined from animal experiments was already reached after the 300 mg dose. Cmax after the 300 mg and 750 mg dose was 2868 and 9266 ng ml-1 with a t 1/2 of 2.54 and 4.78 h, respectively. Concomitant food intake (with the 750 mg and 1125 mg doses) reduced Cmax by approximately 66% and AUC by approximately 40%. With concomitant food intake, the dose-normalized Cmax also decreased significantly by -5.6 (CI: -2.6 to -8.7) ng ml-1 mg-1. The pharmacokinetic variability was largest after the 300 mg and 750 mg dose, resulting in a SD of approximately 50% of the Cmax. Conclusion: NAALADase inhibition with GPI 5693 was safe and tolerable in healthy subjects. Plasma concentrations that were effective in the reversal of hyperalgesia in the chronic constrictive injury animal model of neuropathic pain were obtained at doses of 300, 750 and 1125 mg in the fasted state. Comcomitant food intake reduced Cmax and AUC. CNS effects and GI AEs increased in incidence over placebo only at the 1125 mg dose.

AB - Aim: The aim was to assess the central nervous system (CNS) effects, pharmacokinetics and safety of GPI 5693, an inhibitor of a novel CNS-drug target, NAALADase which is being evaluated for the treatment of neuropathic pain. Methods: This was a double-blind, placebo-controlled, exploratory study in healthy subjects receiving oral GPI 5693 single ascending doses of 100, 300, 750, 1125 mg with a placebo treatment randomly interspersed. An open-label, parallel extension examined the effects of food and sex on the pharmacokinetics of 750, 1125 and 1500 mg doses. Blood samples were collected for pharmacokinetic and biochemical/haematological safety analysis, vital signs, ECG and adverse event checks were performed regularly up to 48 h postdose. Postdose CNS effects were assessed using eye movements, adaptive tracking, electroencephalography (EEC), body sway and Visual Analogue Scales (VAS). Results: CNS effects were mainly observed after the 1125 mg dose, showing a significant decrease of adaptive tracking performance, VAS alertness and VAS mood, and an increase of EEG occipital alpha and theta power. Gastro-intestinal (GI) adverse effects were frequent at higher doses. No clinically significant changes in vital signs or ECG were noted during any of the treatments. The therapeutically relevant concentration range (950-11 100 ng ml-1) as determined from animal experiments was already reached after the 300 mg dose. Cmax after the 300 mg and 750 mg dose was 2868 and 9266 ng ml-1 with a t 1/2 of 2.54 and 4.78 h, respectively. Concomitant food intake (with the 750 mg and 1125 mg doses) reduced Cmax by approximately 66% and AUC by approximately 40%. With concomitant food intake, the dose-normalized Cmax also decreased significantly by -5.6 (CI: -2.6 to -8.7) ng ml-1 mg-1. The pharmacokinetic variability was largest after the 300 mg and 750 mg dose, resulting in a SD of approximately 50% of the Cmax. Conclusion: NAALADase inhibition with GPI 5693 was safe and tolerable in healthy subjects. Plasma concentrations that were effective in the reversal of hyperalgesia in the chronic constrictive injury animal model of neuropathic pain were obtained at doses of 300, 750 and 1125 mg in the fasted state. Comcomitant food intake reduced Cmax and AUC. CNS effects and GI AEs increased in incidence over placebo only at the 1125 mg dose.

KW - Central nervous system

KW - NAALAD-ase-inhibitor

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=23044458183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044458183&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.2005.02396.x

DO - 10.1111/j.1365-2125.2005.02396.x

M3 - Article

C2 - 16042665

AN - SCOPUS:23044458183

VL - 60

SP - 128

EP - 136

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 2

ER -